Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
暂无分享,去创建一个
[1] S. McComb,et al. Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles. , 2023, Molecular therapy. Methods & clinical development.
[2] M. Liedtke,et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results , 2023, Nature Medicine.
[3] Scott D. Brown,et al. CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies , 2022, Frontiers in Immunology.
[4] U. Höpken,et al. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma , 2022, Nature Communications.
[5] Hong Wang,et al. A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML , 2022, Blood.
[6] B. George,et al. Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India , 2022, Bone Marrow Transplantation.
[7] J. Spanholtz,et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies , 2022, Journal of Hematology & Oncology.
[8] M. Caligiuri,et al. The emerging field of oncolytic virus-based cancer immunotherapy. , 2022, Trends in cancer.
[9] D. Gfeller,et al. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization , 2022, Journal for immunotherapy of cancer.
[10] P. Sidaway. Allogeneic CAR T cells show promise , 2022, Nature Reviews Clinical Oncology.
[11] Rui Mao,et al. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better , 2022, Frontiers in Immunology.
[12] Tamara J Laskowski,et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape , 2022, Nature Medicine.
[13] A. Weljie,et al. ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes. , 2022, Cell metabolism.
[14] Qin Dang,et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy , 2022, Theranostics.
[15] J. Martínez-López,et al. Overcoming tumor resistance mechanisms in CAR-NK cell therapy , 2022, Frontiers in Immunology.
[16] Bahram Valamehr,et al. Dual-antigen targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. , 2022, Blood.
[17] Youcai Deng,et al. Natural killer cell homing and trafficking in tissues and tumors: from biology to application , 2022, Signal Transduction and Targeted Therapy.
[18] R. Kiessling,et al. Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality , 2022, Oncoimmunology.
[19] J. Rasko,et al. Locoregional Delivery of CAR-T Cells in the Clinic. , 2022, Pharmacological research.
[20] Xin Ma,et al. CD58 loss in tumor cells confers functional impairment of CAR T cells , 2022, Blood advances.
[21] A. Biondi,et al. The Past, Present, and Future of Non-Viral CAR T Cells , 2022, Frontiers in Immunology.
[22] N. Shah,et al. Bispecific CAR T-cells for B-cell Malignancies , 2022, Expert opinion on biological therapy.
[23] Byung Chan Lee,et al. A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma , 2022, Frontiers in Immunology.
[24] T. Luetkens,et al. Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion , 2022, Leukemia.
[25] Z. Jiang,et al. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma. , 2022, Cytotherapy.
[26] Y. Si,et al. A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells , 2022, Frontiers in Oncology.
[27] C. Ramos,et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion , 2022, Nature Reviews Clinical Oncology.
[28] Z. Berneman,et al. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells , 2022, Journal of Translational Medicine.
[29] J. Lomakin,et al. Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate , 2022, Frontiers in Immunology.
[30] B. George,et al. Distributive Manufacturing of CD19 CAR-T Cells Using Clinimacs Prodigy: Real-World Experience and Cost Analysis in India , 2022, Transplantation and Cellular Therapy.
[31] Leila A. Mashouf,et al. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future , 2022, Frontiers in Immunology.
[32] Soumya Kundu,et al. Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing , 2022, Frontiers in Immunology.
[33] S. McColl,et al. Harnessing the chemokine system to home CAR-T cells into solid tumors , 2022, Cell reports. Medicine.
[34] A. McLellan,et al. Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours , 2022, Cancers.
[35] Quanjun Yang,et al. D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] Quanyin Hu,et al. Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy , 2021, National science review.
[37] T. Mutis,et al. Tumour Escape from CAR-T Cells , 2022, The EBMT/EHA CAR-T Cell Handbook.
[38] P. Neeson,et al. CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors , 2022, Frontiers in Immunology.
[39] E. Verhoeyen,et al. Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies , 2021, Cancers.
[40] P. Corbeau,et al. NK Cells Acquire CCR5 and CXCR4 by Trogocytosis in People Living with HIV-1 , 2021, bioRxiv.
[41] Dariusz M Plewczynski,et al. PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress , 2021, Cancer Immunology Research.
[42] S. Jagannath,et al. Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma , 2021, Blood.
[43] Sagar M. Utturkar,et al. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells , 2021, Proceedings of the National Academy of Sciences.
[44] A. Schambach,et al. Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy , 2021, Frontiers in Immunology.
[45] Shu Wang,et al. piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells , 2021, Molecular therapy. Methods & clinical development.
[46] T. Guo,et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma , 2021, Journal of Hematology & Oncology.
[47] L. Muffly,et al. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia , 2021, Blood advances.
[48] Michael A. Koldobskiy,et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities , 2021, Journal for ImmunoTherapy of Cancer.
[49] A. Esmaeilzadeh,et al. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects , 2021, Stem Cell Reviews and Reports.
[50] Shu Wang,et al. CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model , 2021, Cancer Gene Therapy.
[51] R. Deberardinis,et al. Clinically-relevant T cell expansion protocols activate distinct cellular metabolic programs and phenotypes , 2021, bioRxiv.
[52] Rebecca Borgert. Improving outcomes and mitigating costs associated with CAR T-cell therapy. , 2021, The American journal of managed care.
[53] M. Caligiuri,et al. Hijacking TYRO3 from Tumor Cells via Trogocytosis Enhances NK-cell Effector Functions and Proliferation , 2021, Cancer Immunology Research.
[54] Yumin Li,et al. Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future , 2021, Frontiers in Immunology.
[55] K. Davis,et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial , 2021, Nature Medicine.
[56] S. Luanpitpong,et al. Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies , 2021, Journal of immunology research.
[57] A. Schambach,et al. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123 , 2021, Viruses.
[58] Xiaoming Feng,et al. Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL , 2021, Frontiers in Oncology.
[59] D. Finlay,et al. Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy , 2021, Stem Cell Research & Therapy.
[60] J. Reed,et al. Lymphocytes and Trogocytosis-Mediated Signaling , 2021, Cells.
[61] K. Sanber,et al. Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells , 2021, British journal of haematology.
[62] Yumin Li,et al. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors , 2021, Frontiers in Immunology.
[63] C. Mason,et al. Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells. , 2021, Blood.
[64] S. Woodhouse,et al. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells , 2021, Journal for ImmunoTherapy of Cancer.
[65] H. Karasuyama,et al. The Role of Trogocytosis in the Modulation of Immune Cell Functions , 2021, Cells.
[66] Jianxiang Wang,et al. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy , 2021, Journal of Hematology & Oncology.
[67] O. Ottmann,et al. Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy , 2021, Antibodies.
[68] Arjun Gupta,et al. CAR-T cell persistence in the treatment of leukemia and lymphoma , 2021, Leukemia & lymphoma.
[69] Dacheng Ma,et al. Sense-and-Respond Payload Delivery Using a Novel Antigen-Inducible Promoter Improves Suboptimal CAR-T Activation , 2021, bioRxiv.
[70] J. Marshall,et al. Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer , 2021, Cancers.
[71] Rosalie M Sterner,et al. CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.
[72] R. Gottardi,et al. Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies , 2021, Cancers.
[73] R. Başar,et al. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells , 2021, Frontiers in Immunology.
[74] P. Mangeot,et al. Baboon Envelope Pseudotyped “Nanoblades” Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34+ Cells and Knock-in of AAV6-Encoded Donor DNA in CD34+ Cells , 2021, Frontiers in Genome Editing.
[75] B. Becher,et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma , 2021, Nature Communications.
[76] D. Wainwright,et al. NK cell-based cancer immunotherapy: from basic biology to clinical development , 2021, Journal of Hematology & Oncology.
[77] S. Gottschalk,et al. Allogeneic CAR Cell Therapy—More Than a Pipe Dream , 2021, Frontiers in Immunology.
[78] R. Shivakumar,et al. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide , 2020, Haematologica.
[79] Depei Wu,et al. Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma , 2020, Cancer medicine.
[80] Muhammad Yasir Anwar,et al. A systematic review and meta-analysis of CD-19-specific CAR-T cell therapy in relapsed/refractory acute lymphoblastic leukaemia in paediatrics and young adults: Safety and efficacy outcomes , 2020 .
[81] Z. Berneman,et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma , 2020, Journal of Hematology & Oncology.
[82] Shannon K. Boi,et al. MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects , 2020, Nature Immunology.
[83] K. Sachs,et al. High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment , 2020, bioRxiv.
[84] S. Rosenberg,et al. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] Michael R. Green,et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas , 2020, Nature Medicine.
[86] Jianzhu Chen,et al. CAR-NK cells: A promising cellular immunotherapy for cancer , 2020, EBioMedicine.
[87] F. Gao,et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. , 2020, Blood.
[88] A. Sharpe,et al. When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer , 2020, bioRxiv.
[89] Kole T. Roybal,et al. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. , 2020, Blood advances.
[90] S. Badeti,et al. Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways , 2020, Molecular therapy. Methods & clinical development.
[91] W. Dunn,et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. , 2020, Blood.
[92] S. Eichmüller,et al. Cost of decentralized CAR T‐cell production in an academic nonprofit setting , 2020, International journal of cancer.
[93] N. Nickel,et al. GMP-compliant, automated process for generation of CAR NK cells in a closed system for clinical use , 2020 .
[94] Zhiqiang Wu,et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia , 2020, Journal of Hematology & Oncology.
[95] M. Vitale,et al. Mechanisms of Resistance to NK Cell Immunotherapy , 2020, Cancers.
[96] P. Thall,et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.
[97] S. Thorne,et al. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency , 2020, Journal for ImmunoTherapy of Cancer.
[98] P. Duchateau,et al. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges , 2020, Nature Reviews Drug Discovery.
[99] Shu Wang,et al. CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts , 2019, Molecular therapy oncolytics.
[100] E. Haddad,et al. Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector , 2019, Front. Immunol..
[101] M. Becker-Hapak,et al. Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT) , 2019, Blood.
[102] Xiongfong Chen,et al. Mesothelin Enhances Tumor Vascularity in Newly Forming Pancreatic Peritoneal Metastases , 2019, Molecular Cancer Research.
[103] A. Plückthun,et al. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors , 2019, Clinical Cancer Research.
[104] C. Mackall,et al. Clinical lessons learned from the first leg of the CAR T cell journey , 2019, Nature Medicine.
[105] G. Lucchini,et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR , 2019, Nature Medicine.
[106] M. Raffeld,et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. , 2019, Blood advances.
[107] Marcela V Maus,et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity , 2019, Nature Biotechnology.
[108] C. Gardiner. NK Cell Metabolism and the Potential Offered for Cancer Immunotherapy , 2019, Immunometabolism.
[109] A. Schambach,et al. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering , 2019, Human gene therapy methods.
[110] Yan Sun,et al. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[111] Q. Rao,et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies , 2019, Journal of Hematology & Oncology.
[112] P. George,et al. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations , 2019, Clinical & translational immunology.
[113] E. Pearce,et al. Metabolic interventions in the immune response to cancer , 2019, Nature Reviews Immunology.
[114] H. Atkins,et al. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. , 2019, Transfusion medicine reviews.
[115] R. Cabeza,et al. Present and Future , 2008 .
[116] M. Sadelain,et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape , 2019, Nature.
[117] C. Pui,et al. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia , 2019, Journal of Immunotherapy for Cancer.
[118] K. Curran,et al. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. , 2019, Cancer cell.
[119] E. Moon,et al. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment , 2019, Front. Immunol..
[120] I. Flinn,et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.
[121] D. Porter,et al. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. , 2018, Blood.
[122] K. Takenaka,et al. Reinforce the antitumor activity of CD8+ T cells via glutamine restriction , 2018, Cancer science.
[123] C. Mackall,et al. Tumor Antigen Escape from CAR T-cell Therapy. , 2018, Cancer discovery.
[124] Hans Bitter,et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.
[125] Katayoun Rezvani,et al. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. , 2018, Current opinion in immunology.
[126] C. June,et al. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager , 2018, Cancer Immunology Research.
[127] Omkar U. Kawalekar,et al. CAR T cell immunotherapy for human cancer , 2018, Science.
[128] Bing Wang,et al. An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies , 2018, Leukemia.
[129] J. Orange,et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity , 2018, Leukemia.
[130] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[131] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[132] S. Rosenberg,et al. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[133] A. Lundqvist,et al. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma , 2017, Journal of Immunotherapy for Cancer.
[134] W. Zehring,et al. Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature , 2017, Front. Immunol..
[135] S. Riddell,et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.
[136] W. Wels,et al. A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma , 2017, Front. Immunol..
[137] M. Maus,et al. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies , 2016, Computational and structural biotechnology journal.
[138] R. Brentjens,et al. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. , 2016, Biochemical Society transactions.
[139] M. Perales,et al. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[140] Brian Keith,et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. , 2016, Immunity.
[141] Eva M García-Cuesta,et al. Transfer of the human NKG2D ligands UL16 binding proteins (ULBP) 1–3 is related to lytic granule release and leads to ligand retransfer and killing of ULBP‐recipient natural killer cells , 2015, Immunology.
[142] Hinrich Abken,et al. TRUCKs: the fourth generation of CARs , 2015, Expert opinion on biological therapy.
[143] H. Harigae,et al. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand , 2013, Proceedings of the National Academy of Sciences.
[144] Elaine Coustan-Smith,et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. , 2012, Cytotherapy.
[145] Dean Anthony Lee,et al. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. , 2012, Blood.
[146] L. Erickson,et al. Regulatory roles of the tumor necrosis factor receptor BCMA. , 2012, Critical reviews in immunology.
[147] J. Koch,et al. Mechanisms of Tumor and Viral Immune Escape from Natural Killer Cell-Mediated Surveillance , 2011, Journal of Innate Immunity.
[148] G. Gahrton,et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. , 2010, Cytotherapy.
[149] B. Lindgren,et al. Allogeneic natural killer cells for refractory lymphoma , 2010, Cancer Immunology, Immunotherapy.
[150] S. Agaugué,et al. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. , 2009, Blood.
[151] D. Campana,et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.
[152] Rufina Leung,et al. The Activating NKG2D Ligand MHC Class I-Related Chain A Transfers from Target Cells to NK Cells in a Manner That Allows Functional Consequences1 , 2007, The Journal of Immunology.
[153] P. Moreau,et al. Trogocytosis‐based generation of suppressive NK cells , 2007, The EMBO journal.
[154] S. Chisholm,et al. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[155] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[156] A. R.,et al. Review of literature , 1969, American Potato Journal.
[157] E. N. Nolte-‘t Hoen,et al. Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[158] E. Joly,et al. What is trogocytosis and what is its purpose? , 2003, Nature Immunology.
[159] T. Brown. Observations by immunofluorescence microscopy and electron microscopy on the cytopathogenicity of Naegleria fowleri in mouse embryo-cell cultures. , 1979, Journal of medical microbiology.